EZH2 and atherosclerosis: As a result, further studies have associated dysregulation of EZH2 with various diseases, including CVD (cardiac hypertrophy, fibrosis, atherosclerosis, ischemic heart disease, myocardial regeneration, cardiomyopathy, pulmonary arterial hypertension, atrial fibrillation) (26, 32–37), various solid cancers (lung, breast, endometrial, ovarian, nasopharyngeal, thyroid, liver, prostate, and glioblastoma) (8, 17, 38–40), as well as hematopoietic cancers (Non-Hodgkin's, large B-cell, and follicular lymphoma) (41, 42).